Your cart is currently empty!
CDX2 biomarker testing and adjuvant therapy for stage II colon cancer: An exploratory cost-effectiveness analysis
$11.00
All your purchased models will be available under your account under “Dashboards”
Disease Area (Primary)
Stage II Colon Cancer
First Developed
07/28/2021
Last Developed
08/05/2021
Software Used
R (e.g., heemod, BCEA, dampack, hesim)
Model Sponsor
Academic institution
Intervention
other_adjuvant_chemotherapy
Model Validation Score
– %
Coming Soon In Phase II: You will be able to pay a fee to download the CADTH Tool for your model which includes subaggregated scores.
Results
Testing for CDX2 followed by FOLFOX for CDX2-negative patients had an incremental cost-effectiveness ratio of $5,500/QALY compared to no CDX2 testing and no FOLFOX (6.874 vs. 6.838 discounted QALYs, and $89,991 vs. $89,797 discounted USD lifetime costs). In sensitivity analyses, considering a cost-effectiveness threshold of $100,000/QALY, testing for CDX2 followed by FOLFOX on CDX2-negative patients remains cost-effective for hazard ratios less than 0.975 of the effectiveness of FOLFOX in CDX2-negative patients in reducing the rate of developing a metastatic recurrence.
Conclusion
Testing stage II colon cancer patients’ tumor for CDX2 and administration of adjuvant treatment to the subgroup found CDX2-negative is a cost-effective and high-value management strategy across a broad range of plausible assumptions.
Source File(s)
Model:
Publication File:
Publication File 1:
Publication File 2:
Publication File 3:
Publication File 4:
No link submitted.
No link submitted.
No link submitted.
No link submitted.
Model Review
Only visible for the model owner
Summary
Validation Score
– %
Internal Comments
–